FDAapproval95% confidence
FDA Approves First Generic of Priftin (rifapentine) Tablets
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Gilead; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Food and Drug Administration has approved the first generic of Priftin (rifapentine) tablets, a medication for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis drugs.
Supporting Context
- Therapeutic area
- Infectious Disease · HIV
- Sub-indication
- General
Related signal: FDA Approves Supplement for Biktarvy by Gilead Sciences